Xilio Therapeutics Inc ( (XLO) ) has released its Q1 earnings. Here is a breakdown of the information Xilio Therapeutics Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Xilio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes. The company recently released its earnings report for the first quarter of 2025, highlighting key financial metrics and strategic developments. Xilio reported a net loss of $13.3 million for the quarter, an improvement from the $17.2 million loss in the same period last year, attributed to increased collaboration and license revenue. The company raised $52 million through a collaboration agreement with AbbVie, which includes a $42 million upfront payment and a $10 million private placement. Despite its financial challenges, Xilio’s management remains optimistic about its future, with plans to secure additional capital and continue advancing its product candidates through clinical trials.